Polypeptide from haemophilus influenzae

Abstract

The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

1 - 26 . (canceled) 
     
     
         27 . An isolated polypeptide comprising an amino acid sequence selected from:
 a) an amino acid sequence which has at least 99% identity to an amino acid of SEQ ID Nos: 2 over the entire length of said sequence; and   b) an amino acid sequence which has at least 85% identity to an amino acid sequence selected from SEQ ID Nos: 4, 6, 8 and 10 over the entire length of said sequence.   
     
     
         28 . An isolated polypeptide as claimed in  claim 27  in which the amino acid sequence has at least 95% identity to an amino acid sequence selected from SEQ ID Nos: 4, 6, 8 and 10, over the entire length of said sequence. 
     
     
         29 . The polypeptide as claimed in  claim 27  comprising an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10. 
     
     
         30 . The polypeptide as claimed in  claim 29  consisting of an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10. 
     
     
         31 . An immunogenic fragment of a polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10, over the entire length of said sequence, wherein said fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognizes a polypeptide of SEQ ID Nos: 2, 4, 6, 8 or 10. 
     
     
         32 . The polypeptide of  claim 27  wherein said polypeptide is part of a larger fusion protein. 
     
     
         33 . An isolated polynucleotide encoding a polypeptide of  claim 27 . 
     
     
         34 . An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide selected from SEQ ID Nos: 2, 4, 6, 8 and 10 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide. 
     
     
         35 . An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to a DNA sequence selected from SEQ ID Nos: 1, 3, 5, 7 and 9 over the entire length of said sequence; or a nucleotide sequence complementary to said isolated polynucleotide. 
     
     
         36 . The isolated polynucleotide as claimed in  claim 35  in which the identity is at least 95% to a DNA sequence of SEQ ID Nos: 1, 3, 5, 7 and 9. 
     
     
         37 . The isolated polynucleotide of  claim 34  comprising a nucleotide sequence encoding a polypeptide selected from SEQ ID Nos: 2, 4, 6, 8 and 10. 
     
     
         38 . The isolated polynucleotide of  claim 35  comprising a polynucleotide selected from SEQ ID Nos: 1, 3, 5, 7 and 9. 
     
     
         39 . The isolated polynucleotide of  claim 33  comprising a nucleotide sequence encoding a polypeptide selected from SEQ ID Nos: 2, 4, 6, 8 and 10 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the corresponding DNA sequence of SEQ ID Nos: 1, 3, 5, 7 or 9, or a fragment thereof. 
     
     
         40 . An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to  claim 33 . 
     
     
         41 . A host cell comprising the expression vector or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide of  claim 27 . 
     
     
         42 . A process for producing the polypeptide expressed by the host cell of  claim 41 , comprising culturing the host cell under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium. 
     
     
         43 . A process for expressing a polynucleotide of  claim 33  comprising transforming a host cell with the expression vector comprising said polynucleotide and culturing said host cell under conditions sufficient for expression of said polynucleotide. 
     
     
         44 . An immunogenic composition comprising an effective amount of a immunogenic fragment of  claim 31 , and a pharmaceutically acceptable carrier. 
     
     
         45 . An immunogenic composition comprising an effective amount of a polynucleotide of  claim 35 , and a pharmaceutically effective carrier. 
     
     
         46 . The immunogenic composition according to  claim 44  wherein said composition comprises at least one other non typeable  H. influenzae  antigen. 
     
     
         47 . An antibody immunospecific for a polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid. sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10, over the entire length of said sequence, or an immunological fragment thereof. 
     
     
         48 . A method of diagnosing a non typeable  H. influenzae  infection, comprising identifying a polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10, over the entire length of said sequence, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection. 
     
     
         49 . A therapeutic composition useful in treating humans with non typeable  H. influenzae  disease comprising at least one antibody directed against a polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10, over the entire, length of said sequence, and a suitable pharmaceutical carrier. 
     
     
         50 . A method of generating an immune response in an animal comprising administering an immunogenic composition comprising an immunologically effective amount of a polypeptide comprising an amino acid sequence which has at least 85% identity to an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8 and 10, over the entire length of said sequence, to the animal. 
     
     
         51 . A method of generating an immune response in an animal, comprising administering an immunogenic composition comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence which has at least 85% identity to a DNA sequence selected from SEQ ID Nos: 1, 3, 5, 7 and 9 over the entire length of said sequence, to the animal.